Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

Black Diamond Therapeutics' Silvertinib (BDTX-1535) targets non-classical EGFR mutations in NSCLC, addressing an unmet need left by current standard Osimertinib. Preliminary Phase 2 results for Silvertinib are promising, with full enrollment completed and further data expected in Q4 2025. Early data of Silvertinib in the first line setting will be a major catalyst.

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma, with key phase 2 data expected in Q4 2025. The Servier licensing deal strengthens BDTX's cash position, providing runway into late 2027 and reducing near-term financial risk. Despite a challenging competitive landscape, the Company's targeted approach and early efficacy signals create potential for significant upside if data are positive.

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D.

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.

CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences.

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals.